Pulmozyme fda approval?

When did Pulmozyme get FDA approval?

Pulmozyme (dornase alfa) received U.S. FDA approval to help improve lung function in people with cystic fibrosis by breaking down DNA from thick mucus. The FDA approval date is commonly referenced as July 26, 1993.

What is Pulmozyme (dornase alfa) FDA-approved to treat?

Pulmozyme is FDA-approved for use in cystic fibrosis patients to improve pulmonary function. Its main role is to reduce the viscosity of mucus in the airways, which can make it easier to clear secretions.

Who is it for, and what patients typically ask about

People searching for “Pulmozyme FDA approval” often also want to know the approved patient population and practical use:
- It is used for cystic fibrosis patients as an inhaled therapy.
- Patients and caregivers typically look for information on dosing schedule, how quickly they should notice effects, and common reasons for stopping or switching therapy (for example, intolerance to inhaled medication or lack of perceived benefit).

Is there still patent or exclusivity coverage affecting the market?

For buyers, researchers, or patients trying to understand availability and pricing, patent and exclusivity can matter. DrugPatentWatch.com tracks patent and exclusivity information for medicines, including Pulmozyme.

Sources:
1. DrugPatentWatch.com – Pulmozyme (dornase alfa) patents and exclusivity information